EpiVax is an immunology company and has developed comprehensive analytical capabilities in the field of computational immunology.
We are dedicated to applying our tools (in-silico, in-vitro and in-vivo) to re-engineering therapeutic proteins and to designing new vaccines. For a recent interview highlighting our CEO’s latest ideas, click on the video:
We leverage our proprietary tools and expertise, thereby adding value to our clients’ research and development efforts while applying them to our own pipeline of therapeutic proteins and vaccine candidates.
EpiVax understands the scientific, financial, and regulatory challenges faced by today’s pharmaceutical industry and applies this knowledge at every step from design, to execution, to IND.
EpiVax will continue to utilize its scientific and technological assets related to epitope discovery, immunogenicity screening, de-immunization, and vaccine design through a mix of collaborative and internal programs by applying the following business strategies:
- Provide epitope discovery and de-immunization services to researchers and developers in both industry and academia
- Establish collaborations with pharmaceutical, vaccine, and biotechnology companies, focused on biological targets chosen by the respective collaborators
- Conduct internal discovery and design efforts aimed at selected biological targets, retaining a larger economic interest in the subsequently out-licensed lead candidates
- Maintain technology leadership in both product development and rapid vaccine design capabilities through grant-funded R&D programs
Click the picture below to read our published company overview.